South Korea · Delayed Price · Currency is KRW JW Lifescience Statistics
Total Valuation
JW Lifescience has a market cap or net worth of KRW 222.05 billion. The enterprise value is 245.10 billion.
| Market Cap | 222.05B |
| Enterprise Value | 245.10B |
Important Dates
The next estimated earnings date is Thursday, February 5, 2026.
| Earnings Date | Feb 5, 2026 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
JW Lifescience has 15.48 million shares outstanding.
| Current Share Class | 15.48M |
| Shares Outstanding | 15.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 6.08% |
| Float | 8.56M |
Valuation Ratios
The trailing PE ratio is 4.67.
| PE Ratio | 4.67 |
| Forward PE | n/a |
| PS Ratio | 0.89 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.60 |
| P/FCF Ratio | 8.07 |
| P/OCF Ratio | 5.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.79, with an EV/FCF ratio of 8.90.
| EV / Earnings | 5.15 |
| EV / Sales | 0.99 |
| EV / EBITDA | 3.79 |
| EV / EBIT | 5.18 |
| EV / FCF | 8.90 |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.21 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 0.93 |
| Debt / FCF | 1.77 |
| Interest Coverage | 17.11 |
Financial Efficiency
Return on equity (ROE) is 24.72% and return on invested capital (ROIC) is 9.21%.
| Return on Equity (ROE) | 24.72% |
| Return on Assets (ROA) | 7.71% |
| Return on Invested Capital (ROIC) | 9.21% |
| Return on Capital Employed (ROCE) | 15.50% |
| Revenue Per Employee | 836.02M |
| Profits Per Employee | 160.23M |
| Employee Count | 297 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 6.42 |
Taxes
In the past 12 months, JW Lifescience has paid 11.95 billion in taxes.
| Income Tax | 11.95B |
| Effective Tax Rate | 20.08% |
Stock Price Statistics
The stock price has increased by +27.35% in the last 52 weeks. The beta is 0.42, so JW Lifescience's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +27.35% |
| 50-Day Moving Average | 13,849.80 |
| 200-Day Moving Average | 12,295.15 |
| Relative Strength Index (RSI) | 52.04 |
| Average Volume (20 Days) | 129,349 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, JW Lifescience had revenue of KRW 248.30 billion and earned 47.59 billion in profits. Earnings per share was 3,073.31.
| Revenue | 248.30B |
| Gross Profit | 68.80B |
| Operating Income | 35.25B |
| Pretax Income | 59.54B |
| Net Income | 47.59B |
| EBITDA | 52.64B |
| EBIT | 35.25B |
| Earnings Per Share (EPS) | 3,073.31 |
Balance Sheet
The company has 25.80 billion in cash and 48.85 billion in debt, giving a net cash position of -23.05 billion or -1,488.83 per share.
| Cash & Cash Equivalents | 25.80B |
| Total Debt | 48.85B |
| Net Cash | -23.05B |
| Net Cash Per Share | -1,488.83 |
| Equity (Book Value) | 214.86B |
| Book Value Per Share | 13,875.48 |
| Working Capital | 17.15B |
Cash Flow
In the last 12 months, operating cash flow was 41.12 billion and capital expenditures -13.59 billion, giving a free cash flow of 27.53 billion.
| Operating Cash Flow | 41.12B |
| Capital Expenditures | -13.59B |
| Free Cash Flow | 27.53B |
| FCF Per Share | 1,777.90 |
Margins
Gross margin is 27.71%, with operating and profit margins of 14.20% and 19.17%.
| Gross Margin | 27.71% |
| Operating Margin | 14.20% |
| Pretax Margin | 23.98% |
| Profit Margin | 19.17% |
| EBITDA Margin | 21.20% |
| EBIT Margin | 14.20% |
| FCF Margin | 11.09% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 3.48%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 3.48% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 16.27% |
| Buyback Yield | n/a |
| Shareholder Yield | 3.48% |
| Earnings Yield | 21.43% |
| FCF Yield | 12.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 20, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Apr 20, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
JW Lifescience has an Altman Z-Score of 3.03 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.03 |
| Piotroski F-Score | 5 |